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Conclusions: To our knowledge, this is the first study to directly 
compare the percentage of anatomical coverage of eLN’s by four PTVs 
in the same patient cohort. Potential practical consequences are 
discussed in detail. Knowing the specific risk of each eLN region allows 
to derive a moderate expansion of the primary tumour volume to 
include eLN regions at highest risk without significant normal tissue 
dose increase.  
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Purpose/Objective: Preoperative chemoradiotherapy (CRT) has been 
established as the standard of care for patients with cT3-4 rectal 
cancer. However, a benefit on overall survival (OS) could not be 
demonstrated with the addition of concomitant chemotherapy. We 
explored prospectively preoperative intensity-modulated and image-
guided radiotherapy (IMRT-IGRT) with a simultaneous integrated boost 
(SIB) as an alternative strategy, of which first results showed a limited 
acute toxicity profile and promising 2-year local control (LC). Here, 
we report clinical outcome and late toxicity after a median follow-up 
of 54 months. 
Materials and Methods: A total of 108 patients were treated 
preoperatively with IMRT-IGRT using the Tomotherapy Hi-Art II 
system, delivering a dose of 46 Gy in daily fractions of 2 Gy to the 
mesorectum and draining lymph nodes, without concomitant 
chemotherapy. Fifty-seven patients (53%) displayed an anticipated 
circumferential resection margin (CRM) of less than 2 mm based on 
magnetic resonance imaging and received a SIB to the tumor up to a 
total dose of 55.2 Gy (boost group). Late side effects were scored 
using the National Cancer Institute Common Terminology Criteria for 
Adverse Events version 3.0. 
Results: Grade ≥ 2 late diarrhea was recorded in 11% of the patients. 
The absolute incidence of grade ≥ 3 late gastrointestinal and urinary 
toxicity was 9% and 4%, respectively, with a 13% rate of any grade ≥ 3 
late toxicity. The actuarial 5-year LC, progression-free survival (PFS) 
and OS were 97%, 68%, and 68%. On multivariate analysis, R1 resection 
(CRM ≤ 1 mm) (p=0.03) and pN2 disease (p=0.04) were associated with 
significantly impaired PFS and OS. Dworak grade 3-4 regression 
showed improved PFS on univariate analysis (p=0.03).  
Conclusions: The use of preoperative IMRT-IGRT with a SIB resulted in 
an acceptable late toxicity profile in T3-4 rectal cancer patients. The 
implementation of a SIB in a patient population at risk for local 
recurrence yielded a high 5-year LC rate, comparable to the rates 
observed after preoperative CRT.  
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Purpose/Objective: As neoadjuvant treatment and total mesorectal 
excision (TME) has dramatically improved local control during the last 
two decades, distant recurrences now primarily determine outcome in 
patients with rectal cancer. The introduction of preoperative 
chemoradiotherapy (CRT), however, has also changed the importance 
of histopathological parameters. The objective of this study is to 
evaluate which factors determine outcome, focusing on the 
contribution of clinical factors and histopathological response after 
CRT, in the development of distant recurrences in particular. 
Materials and Methods: Between 2004 and 2008, all consecutive 
patients with MRI-defined locally advanced rectal cancer (LARC), 
without synchronous metastases, treated with CRT (25x2Gy during 
weekdays with capecitabine 825 mg/m2 days 1-33) followed by TME 
after 6-8 weeks, were included. Adjuvant chemotherapy was not 
standard. Central revision of histopathology followed using TNM, 5th 
edition. Histological tumour regression grade (TRG) was scored with a 
4-tier system (complete response, near complete response, response, 
poor response). Univariate and logrank analysis were performed to 
identify predictors and prognosticators. 
Results: For this 107 patients with a median follow-up of 44 months, 
the distal recurrence free interval (DRFI), DFS and OS 3-year rates 
were 82%, 73% and 87%, respectively. Of the 23 patients developing 
distant recurrences, 11 occurred within a year after surgery (Fig 1). 
Slides of the resection specimens were analysed and revealed 18% 
pCR, 13% near pCR, 55% response, and 14% poor response. A positive 
CRM, ypT3-4 and presence of poor prognostic features (lymphangio 
invasion or perineural growth) were associated with a poor response. 
Four of the 19 patients with a pCR still harboured nodal metastases. 
Six of 14 patients with a near pCR still had ypT3 disease and 8/14 
were still node positive. In addition, near pCR was associated with a 
relatively poor outcome: 5 out of 14 patients developed distant 
metastases. TRG was a powerful discriminator of DRFI, DFS and OS. In 
addition ypT, ypN, presence of tumour deposits (TD) and the presence 
of acellular mucin lakes, were associated with a decreased DRFI, and 
remained significant after adjusting for TRG. Whereas ypN, TD, 
mucinous histology and acellular mucin lakes were associated with 
distant recurrence within a year. 
 
 Conclusions: In this well-defined and uniformly treated cohort of 
LARC patients, a ypCR predicts excellent outcome, while patients with 
a near pCR still have a high risk of developing distant recurrences 
(36%). The high number of near pCR patients with ypT3 or ypN1/2 
disease demonstrates that wait and see policies in locally advanced 
rectal cancer patients should be applied with extreme caution and 
care. 
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Purpose/Objective: In rectal cancer, histopathologic complete 
response to neoadjuvant radiation/chemoradiation therapy (RT/CRT) 
commonly translates into long-term survival benefits, and some 
investigators are currently advocating a non-surgical 'wait-and-see' 
approach in patients achieving complete clinical response. Using 
organ-infiltrating rectal cancer as model, we aimed at identifying the 
actual ('true') frequency of tumor down-staging following neoadjuvant 
RT/CRT, by means of determining the false-negative rate of 
conventional histopathologic tumor response evaluation. In doing so, 
we developed the diagnostic procedure of magnetic resonance- (MR) 
guided histopathology. 
Materials and Methods: Ninety-two patients that had received 
neoadjuvant treatment and proceeded to extended total mesorectal 
excision were identified from the institutional database. For each 
patient, the study radiologist and pathologist separately interpreted 
preoperative MR images and histologic preparations from the surgical 
specimen, to determine whether tumor down-staging had resulted. In 
cases of discrepancy after the separate yT staging (52 patients), 
histologic sections were jointly reassessed for residual tumor in areas 
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peripheral to the mesorectal compartment, using MR images as 
guidance for where to inspect. 
 
  
Results: The table summarizes distribution of tumor responses to 
neoadjuvant RT/CRT in the cohort of 92 patients, as determined by 
MR and histopathology separately ('Before procedure' and 'Routine 
evaluation') and by the full procedure of MR-guided histopathology 
('After procedure'). Strikingly, the latter resulted in reclassification of 
23 of the originally categorized ypT0–3 specimens to ypT4 (44.2% of all 
reassessed samples). Omitting nine indeterminate cases (yTX), the 
figures showed that only 27 individuals (32.5%) achieved tumor down-
staging (ypT0–3). Hence, following RT/CRT, 67.5% of organ-infiltrating 
rectal cancer cases were found to remain ypT4, even though half of 
the study population had complete (ypT0; 7.6%) or near-complete 
(sparsely remaining tumor; 43.5%) histomorphologic tumor regression. 
When MR images were used to guide histologic sampling, false-
negative rate of conventional histopathology for detection of ypT4, 
which frequently was undetectable at the separate MR examination, 
was determined to be 41.1%. Five-year estimate for locally recurrent 
disease was 12.7%. 
Conclusions: This response data to neoadjuvant RT/CRT in organ-
infiltrating rectal cancer indicates that ypT4 outcome is frequently 
under-estimated in routine evaluation. The observations also suggest 
that these tumors predominantly respond by a process of 
fragmentation into microscopic residual disease. Because remaining 
tumor cells may be clonogenic, this information should be of note for 
multidisciplinary teams in the formal decision-making process for the 
individual patient, particularly in a time of increasing focus on organ 
preservation treatment strategies in rectal cancer. 
 
   
  
